Your browser doesn't support javascript.
loading
A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis.
Modonutti, Daniele; Majdalany, Sami E; Corsi, Nicholas; Li, Pin; Sood, Akshay; Dalela, Deepansh; Jamil, Marcus L; Hwang, Clara; Menon, Mani; Rogers, Craig G; Trinh, Quoc-Dien; Novara, Giacomo; Abdollah, Firas.
Affiliation
  • Modonutti D; Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan, USA.
  • Majdalany SE; Department of Surgery, Oncology and Gastroenterology-Urology, University Hospital of Padova, Padova, Italy.
  • Corsi N; Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan, USA.
  • Li P; Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan, USA.
  • Sood A; Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan, USA.
  • Dalela D; Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan, USA.
  • Jamil ML; Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan, USA.
  • Hwang C; Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan, USA.
  • Menon M; Department of Internal Medicine, Division of Hematology/Oncology, Henry Ford Health System, Detroit, Michigan, USA.
  • Rogers CG; Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan, USA.
  • Trinh QD; Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan, USA.
  • Novara G; Division of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Abdollah F; Department of Surgery, Oncology and Gastroenterology-Urology, University Hospital of Padova, Padova, Italy.
Prostate ; 82(13): 1293-1303, 2022 09.
Article in En | MEDLINE | ID: mdl-35790016
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans / Male Language: En Journal: Prostate Year: 2022 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans / Male Language: En Journal: Prostate Year: 2022 Document type: Article Affiliation country: United States Country of publication: United States